SCHEMBL6484094

SCHEMBL6484094

Cc1cc(Cc2ccc(F)cc2)c(=O)n2cc(C(=O)O)sc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
TRPA1 O75762 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
FPR1 P21462 2/20 0.38
FPR2 P25090 1/20 0.35
CNR2 P34972 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MAPK1 P28482 1/20 0.34
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6814152 0.89 MEN1 (0.37) LMNATRPA1MEN1KMT2APDE3B
SCHEMBL6814146 0.88 FPR1 (0.38) LMNATRPA1MEN1KMT2APDE3B
SCHEMBL6814150 0.81 TRPA1 (0.51) TRPA1NPSR1MAPK1MAPTSMN1; SMN2
SCHEMBL6484773 0.78 MEN1 (0.41) LMNAMEN1KMT2APDE3BPDE3A
SCHEMBL6488185 0.76 TRPA1 (0.53) LMNATRPA1MAPTALDH1A1
SCHEMBL6485436 0.75 CNR2 (0.40) LMNAMEN1KMT2APDE3BPDE3A
SCHEMBL6476120 0.75 TRPA1 (0.54) LMNATRPA1MAPT
SCHEMBL6231949 0.72 TRPA1 (0.73) TRPA1NPSR1MAPK1
SCHEMBL6288728 0.72 LMNA (0.45) LMNAMEN1KMT2ACNR2GPR55
SCHEMBL6486582 0.69 MAPT (0.46) LMNATRPA1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 LMNA 2417/4885TRPA1 4030/4885MEN1 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.